RISING concerns over crop diseases and sustainable food production continue to drive investment into agricultural biotechnology, with UK-based Resurrect Bio securing € 8.8 million( US $ 10.3 million) in Series A funding to expand its diseaseresistant crop technologies. The London-headquartered startup said the oversubscribed funding round was led by Corteva through its Corteva Catalyst platform, alongside participation from several investors including Calculus Capital, Pymwymic, UKI2S, SynBioVen and AgFunder.
|
The latest investment raised the company’ s total funding to approximately US $ 12.4 million since its founding in 2022.
Originally spun out from The Sainsbury Laboratory in Norwich, Resurrect Bio focuses on developing crop protection technologies that strengthen natural plant immunity against diseases, reducing reliance on chemical treatments.
Its research combines artificial intelligence, plant science and functional biology to identify and reactivate resistance traits already present within crop genetics.
Chief Executive Officer Cian Duggan said the company was now
|
looking to deepen collaboration with seed companies and plant breeders.
“ The strength of this raise reflects growing conviction in what we’ re building: a scalable, AI-driven platform for resurrecting disease resistance in the world’ s most important crops. It’ s also a validation of what’ s possible when you combine the UK’ s world-class plant science base with commercial ambition to translate it into real-world impact.
“ We’ re expanding our team, deepening our platforms, and actively seeking joint development agreements with seed companies and breeders who want to bring durable resistance traits to farmers,” he said.
|
The company plans to channel the funding into scaling its FloraFold AI discovery platform and expanding research to accelerate the development of disease-resistant crop varieties.
Investment Director at Calculus Capital, Elizabeth Klein-Edmonds, said disease pressure remained a major challenge for global agriculture.
“ Crop disease remains a major and often overlooked challenge in global agriculture. Resurrect Bio’ s innovative gene-editing platform, which restores native disease-resistance genes in crops, offers a promising solution by reducing dependence on chemicals and boosting yields,” she explained.
Earlier in Mar 2026, the company announced a collaboration with Corteva Agriscience to develop disease resistance in corn, highlighting growing industry interest in biotechnology-driven crop resilience solutions.
|